Glaucoma News and Research

Latest Glaucoma News and Research

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP).

5 Sep 2012

Scientists identify three new genes associated with Primary Angle Closure Glaucoma

Singapore scientists have identified three new genes associated with Primary Angle Closure Glaucoma (PACG), a leading cause of blindness in Chinese people. PACG affects 15 million people worldwide, 80% of whom live in Asia.

5 Sep 2012

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Glaucoma is normally caused by increased pressure of aqueous humour fluid in the eye. A defining feature of this disease is destruction of a particular type of cells in the retina called retinal ganglion cells and excavation of the optic disc region.

31 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.

21 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Johns Hopkins CIDR receives NIH contract to study genetic diseases

The Johns Hopkins Center for Inherited Disease Research (CIDR) program contract, which provides up to $101 million in research funding from the National Institutes of Health (NIH) to study the genetic contribution to human diseases, has been renewed for another five years.

13 Aug 2012

Worldwide data reveal gaps in elderly eye care

Worldwide eye examination rates among older adults are very low, despite this age group being recommended to have an eye test at least every 1–2 years, say researchers from Canada.

10 Aug 2012

Healthcare professionals receive SingHealth Duke-NUS Scientific Congress abstract awards

Results of the highly anticipated Best Oral Presentation and Best Poster Awards were announced at SingHealth Duke-NUS Scientific Congress 2012, held on 3 and 4 August 2012 at the Raffles City Convention Centre.

8 Aug 2012

$Older Medicare patients have reduced risk of hip fracture following cataract surgery$

Older Medicare patients have reduced risk of hip fracture following cataract surgery

Medicare patients 65 years and older who underwent cataract surgery had a lower odds of hip fracture 1 year after the procedure when compared with patients with cataract who did not have cataract surgery, according to a study in the August 1 issue of JAMA.

1 Aug 2012

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced the nationwide availability of ZETONNA (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older.

30 Jul 2012

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Scientists at the Singapore Eye Research Institute (SERI) and Nanyang Technological University (NTU) have developed an innovative way to combat post-surgical scarring for glaucoma patients.

30 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

AHAF announces glaucoma and macular degeneration research grants

The American Health Assistance Foundation, a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world.

26 Jul 2012

Early-age cataract surgery increases central corneal thickness

When congenital cataract surgery is performed at an early age, central corneal thickness increases, show study results published in the British Journal of Ophthalmology.

25 Jul 2012

Ocular Therapeutix announces results from sustained release OTX-TP1 study on glaucoma

Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.

24 Jul 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Number of blind persons decline in Germany

The numbers of people in Germany who are blind or visually impaired is going down. Robert P. Finger and his co-authors present their findings in the current edition of Deutsches -rzteblatt International.

21 Jul 2012

Glaucoma News and Research

Latest Glaucoma News and Research

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

Scientists identify three new genes associated with Primary Angle Closure Glaucoma

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Johns Hopkins CIDR receives NIH contract to study genetic diseases

Worldwide data reveal gaps in elderly eye care

Healthcare professionals receive SingHealth Duke-NUS Scientific Congress abstract awards

Older Medicare patients have reduced risk of hip fracture following cataract surgery

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Scientists discover new way to combat post-surgical scarring for glaucoma patients

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

AHAF announces glaucoma and macular degeneration research grants

Early-age cataract surgery increases central corneal thickness

Ocular Therapeutix announces results from sustained release OTX-TP1 study on glaucoma

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

Number of blind persons decline in Germany

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Glaucoma News and Research

Latest Glaucoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in